In a notable shift in sentiment, UBS analyst Tasso Vasconcellos issued a Sell rating on Braskem S.A. (BAK) on September 16, 2026. With the stock currently trading at $2.10 and a price target set at $4, this downgrade highlights concerns regarding the company’s financial performance and outlook, prompting investors to reassess their positions in the stock.
Recent Price Action
Braskem’s stock has been on a tumultuous path recently, reflecting broader market conditions and investor sentiment. The stock price experienced a decline of 13.1% in the latest week, falling to $2.10, which is starkly down from a 52-week high of $63.36. This price plunge corresponds with a shift in investor confidence, evident in recent trading volumes that totaled approximately 1.84 million shares traded, compared to an average volume of 2.43 million. With a market capitalization of $727 million and a beta of 0.726, Braskem exhibits comparatively lower volatility, but the recent performance challenges raise red flags for potential investors.
Historical Performance
Over the past 30 days, Braskem has demonstrated a recovery with a notable 12.6% increase, while its quarterly performance reflects a robust 27.7% gain. However, these short-term gains are overshadowed by a longer-term decline of 26% over the past year, indicating persistent challenges for the company amid a fluctuating market dynamic. The underlying volatility is also noteworthy, with a weekly volatility rate of 4.62% and a monthly volatility rate of 4.28%, suggesting that while there may be opportunities for rebound, significant risk lurks for potential investors.
Earnings Analysis
Braskem’s most recent earnings report revealed an earnings per share (EPS) of $1.08, falling short of the estimated EPS of $1.21. This disappointing result reflects a surprise factor of -10.7%, indicative of the company’s struggle to meet market expectations. In contrast, the previous earnings report demonstrated a remarkable surprise of 234.5%, where EPS of $0.69 exceeded the estimate of $0.206. Such volatility in earnings performance raises questions about Braskem’s profitability and operational effectiveness, reinforcing UBS’s bearish perspective.
Consensus Ratings
Currently, Braskem’s consensus rating is starkly negative, with a single Sell rating on record, a stark contrast to absent Buy or Hold ratings. This solitary rating from UBS, alongside an average price target of $4—consistent with the lone analyst projection—suggests a lack of confidence among financial analysts regarding the company’s near-term outlook. The uneasy mood surrounding Braskem is encapsulated by the firm’s reserved stance in its latest assessments.
Stock Grading & Fundamental View
Braskem S.A. has been assigned a Stocks Telegraph Grade (ST Score) of 44. This score indicates weak fundamentals and varying performance metrics that reflect challenges faced by the company. Investors often interpret ST Scores beneath 50 as signals of caution, suggesting that Braskem is presently not positioned as a leader within its sector.
Conclusion
For prospective investors, Braskem S.A. currently presents a high-risk venture underscored by recent declines in stock performance and disappointing earnings results. The company’s downgrade to Sell reflects an urgent need for a robust turnaround strategy to regain market trust. The current profile may appeal primarily to risk-seeking investors who are willing to absorb short-term volatility in hopes of capitalizing on potential market corrections; however, the substantial risks tied to its financial outlook cannot be overlooked. Investors should remain vigilant in monitoring Braskem’s trajectory, as its path forward is crucial for any investment decisions.